Sonia Reyes | Feb 28, 2026 A prospective phase II trial at ASCO GU 2026 found that an LLM-based AI communication agent reduced anxiety in prostate cancer patients before surgery while easing the administrative burden on clinical staff.
Sonia Reyes Oncology Care | Feb 28, 2026 Phase 3 LITESPARK-022 found that adjuvant pembrolizumab plus belzutifan significantly improved disease-free survival over pembrolizumab alone in clear cell RCC, potentially establishing a new standard of care.
Sonia Reyes Precision Medicine | Feb 27, 2026 The CLIMATE prospective cohort study found miR-371a-3p surpassed conventional tumor markers for detecting residual testicular germ cell tumor, potentially enabling more precise active surveillance.
Sonia Reyes Oncology Care | Feb 27, 2026 KEYNOTE-B15 found that perioperative enfortumab vedotin plus pembrolizumab significantly outperformed cisplatin-based chemotherapy in cisplatin-eligible muscle-invasive bladder cancer, setting a new treatment benchmark.
Sonia Reyes Oncology Care | Feb 26, 2026 Phase 3 LITESPARK-011 showed an oral belzutifan/lenvatinib combination outperformed cabozantinib in advanced clear cell RCC after immunotherapy, with FDA review due October 2026.
Keywords: renal cell carcinoma, belzutifan, lenvatinib, HIF-2alpha, LITESPARK-011
George Padron Oncology Care | Feb 26, 2026 Final OS data from PEACE-3 show radium-223 plus enzalutamide extended median survival by 5.6 months in mCRPC with bone metastases, supporting it as a first-line combination option.
Only Healthcare Today
Covering Clinical Healthcare, Access and Cost
1 Hewitt Square, Suite 139
East Northport, NY 11731
🔎︎
